Immune Checkpoint Inhibitor Exposure During Pregnancy: A Systematic Review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026
DOI: 10.1002/phar.70115 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Verfasst von Casey L Keller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Texas Health Harris Methodist Hospital Fort Worth, Fort Worth, Texas, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pregnancy Complications, Neoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have been widely implemented in current oncology practice. However, there is limited data regarding ICI administration in pregnancy. This systematic review aims to evaluate the risk–benefit of ICI exposure in pregnant women. We conducted searches in databases including PubMed, Scopus, Web of Science, and Embase from January 1, 2011 through April 30, 2025. Included studies were those that involved women with a cancer diagnosis who received ICI treatment while pregnant and had clinical findings of the fetus post‐ICI treatment. Methodological quality and potential sources of bias were assessed using Joanna Briggs Institute Critical Appraisal Tools. The search generated 2539 citations. After removal of 696 duplicates, a total of 1843 citations were screened. Twenty case reports and three retrospective studies were included in the systematic review. Fetal complications and fetal immune‐related adverse events among the case reports were at 23% and 11.5%, respectively. Preterm delivery occurred in 54% of case reports, and no fetal mortalities were reported. Regarding the observational studies, preterm delivery occurred in 20.9%–25.5% of cases, fetal mortality occurred in 2.2%–15.3% of cases, intrauterine growth restriction occurred in 6.5%–7.1% of cases, and complications attributable to prematurity were reported in 2.6%–5.5% of cases. The data from this systematic review suggests that the risk for fetal complications may be lower than previously reported. As ICIs continue to expand their role in the treatment of malignancy, their use in pregnancy is more likely to come into clinical question. Clinicians should approach ICI use in pregnancy with individualized, multi‐disciplinary risk–benefit discussions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Texas Health Harris Methodist Hospital Fort Worth, Fort Worth, Texas, USA.
ORCID-Profile: Casey L Keller, Kristina C Hermanson, Ryan M Schuller, Saeed K Alzghari
Zitieren
APA
Keller, C. L., Hermanson, K. C., Schuller, R. M., & Alzghari, S. K. (2026). Immune Checkpoint Inhibitor Exposure During Pregnancy: A Systematic Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70115
Vancouver
Keller CL, Hermanson KC, Schuller RM, Alzghari SK. Immune Checkpoint Inhibitor Exposure During Pregnancy: A Systematic Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70115
BibTeX
@article{Keller2026,
author = {Keller, Casey L and Hermanson, Kristina C and Schuller, Ryan M and Alzghari, Saeed K},
title = {Immune Checkpoint Inhibitor Exposure During Pregnancy: A Systematic Review},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
doi = {10.1002/phar.70115}
}
EUVIMED